Skip to main content
SpringerLink
Log in

Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Gonadotropin-releasing hormone analogs (GnRH-A) have been added to the armentarium in the therapy of hormone-dependent breast cancer in premenopausal women. The effect of chronic GnRH-A-treatment in premenopausal women is based on the suppression of the hypothalamus-pituitary-ovarian axis and the reduction of sex-steroid serum levels. In addition, a number of experimental and clinical data have been accumulated indicating a direct action of GnRH-A on breast cancer cells and tissue. In this study we analyzed 235 human breast cancer biopsies for specific GnRH-A-binding. We demonstrate high affinity GnRH-A binding sites in human breast cancer tissues. The evaluation of clinical data showed no correlation of the level of GnRH-A-binding with classical tumor parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kaufmann M: Zoladex in treatment of premenopausal metastatic breast cancer patients. Hormone Res 32 (suppl 1): 202–205, 1989

    Google Scholar 

  2. Klijn JGM, De Jong FH, Lamberts SWJ, Blankenstein MA: LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873, 1985

    Google Scholar 

  3. Nicholson RI, Walker KJ, McClelland RA, Dixon A, Robertson RI, Blamey RW: Zoladex plus tamoxifen versus zoladex alone in pre- and peri-menopausal metastatic breast cancer. J Steroid Biochem Molec Biol 37: 989–995, 1990

    Google Scholar 

  4. Kovacs M, Mezö I, Seprödi J, Csernus V, Teplan I, Flerko B: Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-gonad system. Peptides 10: 925–931, 1989

    Google Scholar 

  5. Rabin D, McNeil LW: Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J Clin Endocrinol Metab 51: 873–876, 1980

    Google Scholar 

  6. Crighton IL, Dowsett M, Lal A, Smith IE: Use of luteinizing hormone-releasing hormone agonist (leuprolin) in advanced post-menopausal breast cancer: clinical and endocrine effects. Br J Cancer 60: 644–648, 1989

    Google Scholar 

  7. Waxmann JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA: The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15: 171–173, 1985

    Google Scholar 

  8. Plowman PN, Nicholson RI, Walker KJ: Remission of postmenopausal breast cancer during treatment with the luteinising hormone-releasing hormone agonist ICI 118630. Br J Cancer 54: 903–909, 1986

    Google Scholar 

  9. Schwartz L, Guiochet N, Keiling R: Two partial remissions induced by an LHRH analogue in two postmenopausal women with metastatic breast cancer. Cancer 62: 2498–2500, 1988

    Google Scholar 

  10. Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4: 521–528, 1989

    Google Scholar 

  11. Srkalovic G, Wittliff JL, Schally AV: Detection and partial characterization of receptors for [D-Trp-6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841–1846, 1990

    Google Scholar 

  12. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R: Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25: 215–221, 1989

    Google Scholar 

  13. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425–432, 1987

    Google Scholar 

  14. Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV: Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor binding ability to rat pituitary and human breast cancer membranes. Endocrinology 124: 946–955, 1989

    Google Scholar 

  15. Kiesel L, Kaufmann M, Haeseler F, Klinga K, von Holst T, Schmidt W, Runnebaum B: GnRH-Rezeptoren im menschlichen Mammakarzinomgewebe. Geburtsh Frauenheilk 48: 420–424, 1988

    Google Scholar 

  16. Vincze B, Palyi I, Daubner D, Kremmer T, Szamel I, Bodrogi I, Sugar J, Seprödi J, Mezö I, Teplan I: Influence of luteinizing hormone-releasing hormone agonists on mammary carcinoma cell lines and their xenografts. J Steroid Biochem Molec Biol 38: 119–126, 1991

    Google Scholar 

  17. Srkalovic G, Szende B, Redding TW, Groot K, Schally AV: Receptors for D-trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: 209–218, 1989

    Google Scholar 

  18. Blankenstein MA, Henkelman MS, Klijn JGM: Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21: 1493–1499, 1985

    Google Scholar 

  19. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233, 1985

    Google Scholar 

  20. Mullen P, Scott WN, Miller WR: Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63: 930–932, 1991

    Google Scholar 

  21. Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV: Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 1648–1651, 1989

    Google Scholar 

  22. Szende B, Zalatnai A, Schally AV: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86: 1643–1647, 1989

    Google Scholar 

  23. Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV: Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LHRH and somatostatin. Breast Cancer Res Treat 14: 307–314, 1989

    Google Scholar 

  24. Keri G, Balogh A, Szöke B, Teplan I, Csuka O: Gonadoptropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Tumor Biol 12: 61–67, 1991

    Google Scholar 

  25. Kiesel L, Sandow J, Bertgres K, Jerabek-Sandow G, Trabant H, Runnebaum B: Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. J Clin Endocrinol Metab 68: 1167–1173, 1989

    Google Scholar 

  26. Greenwood FC, Hunter WH, Glower JS: The preparation of131 I labelled growth hormone of high specific radioactivity. Biochemistry 89: 114–123, 1963

    Google Scholar 

  27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976

    Google Scholar 

  28. Scatchard G: The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 51: 660–672, 1949

    Google Scholar 

  29. Chamness GC, McGuire WL: Scatchard plots: common errors in correction and interpretation. Steroids 26: 538–542, 1975

    Google Scholar 

  30. Eidne KA, Flanagan CA, Millar RP: Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229: 989–991, 1985

    Google Scholar 

  31. Williamson DF, Parker RA, Kendrick JS: The Box Plot: a simple visual method to interpret data. Ann Intern Med 110: 916–921, 1989

    Google Scholar 

  32. Gonzalez-Barcena D, Ibarro-Olmos MA, Garcia-Carrasco F, Gutierrez-Samperio C, Comaru-Schally AM, Schally AV: Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43: 313–317, 1989

    Google Scholar 

  33. Jackson IM, Matthews MJ, Diver JMJ: LHRH analogues in the treatment of cancer. Cancer Treatment Rev 16: 161–175, 1989

    Google Scholar 

  34. Santen RJ, Manni A, Harvey H: Gonadotropin-releasing hormone (GnRH) analogs for the treatment of breast and prostatic carcinoma. Breast Cancer Res Treat 7: 129–145, 1986

    Google Scholar 

  35. Miller WR: Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Molec Biol 37: 467–480, 1990

    Google Scholar 

  36. Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai RZ, Szepeshazi K, Radulovic S: Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies. J Steroid Biochem Molec Biol 37: 1061–1067, 1990

    Google Scholar 

  37. Redding TW, Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81: 248–252, 1984

    Google Scholar 

  38. Bramley TA, Menzies GS, Baird DT: Specificity of gonadotrophin-releasing hormone binding sites of the human corpus luteum: comparison with receptors of rat pituitary gland. J Endocrinol 108: 323–328, 1986

    Google Scholar 

  39. Currie AJ, Fraser HM, Sharpe RM: Human placental receptors for luteinizing hormone-releasing hormone. Biochem Biophys Res Commun 99: 332–338, 1981

    Google Scholar 

  40. Latouche J, Jordan D, Crumeyrolle-Arias M, Kopp N, Augendre-Ferrante B, Cedard L, Haour F: GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125: 1739–1741, 1989

    Google Scholar 

  41. Wiznitzer A, Marbach M, Hazum E, Insler V, Sharoni Y, Levy J: Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Commun 152: 1326–1331, 1988

    Google Scholar 

  42. Segal T, Levy J, Sharmis Y: GnRH analogs stimulate phospholipase C activity in mammary tumor membranes: Modulation by GTP. Mol Cell Endocrinol 53: 239–243, 1987

    Google Scholar 

  43. Neri C, Colomb E, Roux-Dosseto M, Martin PM: Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF-7 breast cancer cells. Anticancer Res 11: 411–416, 1991

    Google Scholar 

  44. Seppälä M, Wahlström T: Identification of luteinizing hormone-releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer 26: 267–268, 1980

    Google Scholar 

  45. Ciocca DR, Puy LA, Fasoli LC, Tello I, Aznar JC, Gago FE, Papa SI, Sonego R: Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat 15: 175–184, 1990

    Google Scholar 

  46. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T: Effects of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinomain vivo. Anti Cancer Drugs 3: 109–116, 1992

    Google Scholar 

  47. EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9: 379–381, 1973

    Google Scholar 

Download references

Author information

Author notes

  1. Ludwig Kiesel

    Present address: Dept. of Gynaecology and Obstetrics, University of Tuebingen, Schleichstr. 4, W-7400, Tuebingen, Germany

  2. Klaus H. Baumann

    Present address: Lombardi Cancer Research Center, Georgetown University Medical Center, S-174, Reservoir Rd. NW, 20007, Washington, DC, USA

Authors and Affiliations

  1. Department of Gynaecology and Obstetrics, University of Heidelberg, Germany

    Klaus H. Baumann, Ludwig Kiesel, Manfred Kaufmann, Gunther Bastert & Benno Runnebaum

Authors
  1. Klaus H. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludwig Kiesel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Kaufmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gunther Bastert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Benno Runnebaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baumann, K.H., Kiesel, L., Kaufmann, M. et al. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Tr 25, 37–46 (1993). https://doi.org/10.1007/BF00662399

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00662399

Key words

Search

Navigation